Lung Cancer
-
Merck Halts Two Phase III Clinical Trials
Drug development is not easy, and we pay tribute to the heroes of innovative drug development!
-
【Product for Licensing】CLDN6 X 4-1BB bispecific antibody
If interested, please contact DrugTimes BD Team at BD@drugtimes.cn. Many thanks!
-
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC
Monotherapy Ivonescimab Achieved Clinically Meaningful PFS Benefit in HARMONi-2 Tri…
